Compounds > ljc 10627
Page last updated: 2024-08-25

ljc 10627 and dibekacin

ljc 10627 has been researched along with dibekacin in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lombardo, F; Obach, RS; Waters, NJ1
Hikida, M; Kawabata, T; Maebashi, K; Niida, M; Sakakibara, S; Takata, T1
Anandan, S; Balaji, V; Falagas, ME; Rajenderan, S; Sahni, RD; Tansarli, GS1

Other Studies

3 other study(ies) available for ljc 10627 and dibekacin

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
[Combined effects of arbekacin with biapenem against in vitro and in vivo model of a mixture of MRSA and Pseudomonas aeruginosa].
    The Japanese journal of antibiotics, 2004, Volume: 57, Issue:3

    Topics: Aminoglycosides; Animals; Anti-Infective Agents; Dibekacin; Disease Models, Animal; Drug Combinations; Drug Resistance, Bacterial; Drug Therapy, Combination; Male; Methicillin Resistance; Mice; Mice, Inbred ICR; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Staphylococcus aureus; Thienamycins

2004
Determination of MIC distribution of arbekacin, cefminox, fosfomycin, biapenem and other antibiotics against gram-negative clinical isolates in South India: a prospective study.
    PloS one, 2014, Volume: 9, Issue:7

    Topics: Acinetobacter; Anti-Bacterial Agents; Cephamycins; Dibekacin; Drug Resistance, Multiple, Bacterial; Escherichia coli; Fosfomycin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; India; Klebsiella; Microbial Sensitivity Tests; Prospective Studies; Pseudomonas aeruginosa; Thienamycins

2014